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Abstract
Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT)
consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of
these two interventions are currently under discussion. We now raise the question whether both RIT consolidation
and rituximab maintenance should be used together aiming to augment the results achievable with R-
chemotherapy.
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Letter to the Editor
The recent review of T.M. Illidge on radioimmunother-
apy (RIT) of lymphoma highlighted the inherent poten-
tial of this particular treatment [1]. While convinced of
the efficacy of RIT he regretted the low implementation
of RIT in current clinical practice.
We would like to elaborate further on the biological
agents that have shown efficacy in treatment of follicular
lymphoma. In a small series of relapsed indolent lym-
phoma patients treated in Switzerland with 131I-tositu-
momab (Bexxar
®,G l a x o S m i t h K l i n e ,B r e n t f o r d ,U K ) ,w e
experienced several long-lasting complete remissions
with six of 12 patients (50%) reaching 10-years progres-
sion free survival without any further treatment [2].
Similar 10-year progression-free survivals after
131I-tosi-
tumomab in relapse have been reported by another
group, though at a somewhat lower rate [3]. The South-
west Oncology Group (SWOG) has demonstrated that
67% of follicular lymphoma patients remained progres-
sion free more than 5 years after consolidation of
CHOP chemotherapy with
131I-tositumomab [4]. Yet,
another group has communicated a 50% complete
response (CR) rate after 10 years following an initial
treatment using abbreviated fludarabine combined with
131I-tositumomab [5]. A high number of persistent CRs
at 5 to 6 years was also reported for
131I-tositumomab
alone in the initial treatment of follicular lymphoma [6].
High efficacy of RIT with 90Y-ibritumomab has also
been reported repeatedly including a report demonstrat-
ing 5-year relapse free survival in about 20% of relapsed
patients [7]; however, 10-year observations are currently
not available to us.
90Y-ibritumomab (Zevalin
®, Spectrum Pharmaceuti-
cals, Henderson, NV, USA) is the only RIT currently
approved in Europe, and its successful use in consolida-
tion treatment following chemotherapy has been well
documented [8]. On the other hand, rituximab
(Mabthera
®,R i t u x a n
®, Roche Ltd., Genentech, Basel,
Switzerland) maintenance treatment after R-chemother-
apy was recently shown to improve the relapse-free sur-
vival in a large phase III study [9].
Several reports have documented similar efficacies of
RIT consolidation and rituximab maintenance, though
these approaches have not been formally tested in a ran-
domized trial. Both complementary treatments have
moderate and/or transient side effects. The mode of
action of these two added therapies, however, are differ-
ent. Rituximab maintenance is an immunotherapy while
131I-tositumomab and
90Y-ibritumomab are targeted
radiation therapies administered in combination with
two injections of moderate amounts of unlabeled anti-
body. The latter approach is supported by long-standing
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curative when used as initial treatment for localized fol-
licular lymphoma [10]. We envision a similar potential
for RIT given in advanced disease either alone or com-
bined with chemotherapy, as initial treatment or in
relapse [2,3,5].
The 10-year progression-free survival as observed after
131I-tositumomab either alone or combined with che-
motherapy, upfront or at relapse of follicular lymphoma,
appears to be an important milestone. It is anticipated
that this approach might afford a low recurrence rate in
subsequent years, analogous to that observed after exter-
nal beam radiotherapy [10]. The low-energy electrons
emitted by
131I are also prone to eradicate microscopic
disease, as has been shown by others and us in RIT of
small-sized lung or liver metastatic disease, respectively
[11,12].
Further improved biological efficacy in NHL might be
achieved by combining anti-CD20 rituximab treatment
with other antibodies directed against other antigens,
such as anti-CD22 or anti-CD40, utilizing humanized
antibodies, or novel anti-CD20 antibodies with modified
Fc domains providing increased affinity for Fc receptors
and improved effector functions as discussed previously
[13,14].
In current practice, rituximab has appropriately
assumed a dominant position in treatment of lymphoma
both in combination with chemotherapy and as mainte-
n a n c e[ 9 ] .W en o wr a i s et h eq u e s t i o nw h e t h e rb o t h
rituximab and RIT should be used together as comple-
mentary methods to augment the results achievable with
chemotherapy and whether this combined modality
approach might afford additive or synergistic benefit.
This strategy might also allow reducing chemotherapy
as has been shown with abbreviated fludarabine com-
bined with RIT [5]. An attenuated R-CHOP as recently
described for elderly patients could possibly be envi-
saged in such a triple therapy approach [15].
We acknowledge that there is currently little published
data demonstrating the efficacy of anti-CD20 RIT fol-
lowing rituximab-containing induction chemotherapy
regimens. This information gap will be partially reme-
died by a phase II study investigating this combined
approach that has recently been piloted by SWOG in
the NCT00770224 trial, which is assessing the toxicity
and efficacy of R-CHOP induction chemotherapy fol-
lowed by
131I-tositumomab consolidation and 4 years of
rituximab maintenance. This study will assess the poten-
tial impact of administering rituximab anti-CD20 anti-
body with CHOP prior to anti-CD20 RIT [16], though
in this trial rituximab was deliberately omitted from the
last two cycles of CHOP chemotherapy, to minimize
blocking of CD20 antigenic sites prior to RIT. If favor-
able results are achieved in this phase II trial, a phase III
randomized study comparing this “triple” approach with
maintenance rituximab alone or consolidation RIT alone
following induction with R-chemotherapy would be
warranted.
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